Literature DB >> 7507282

Loss of conserved cysteine residues in the attachment (G) glycoprotein of two human respiratory syncytial virus escape mutants that contain multiple A-G substitutions (hypermutations).

P Rueda1, B García-Barreno, J A Melero.   

Abstract

Two escape mutants (R10c/1 and R10c/10) of the human respiratory syncytial (RS) virus Long strain were selected after serial passage in the presence of monoclonal antibody c793 directed against the G glycoprotein. This antibody recognizes an epitope which is shared by all viruses of the two antigenic subgroups in which human RS virus isolates have been subdivided. The mutant viruses had lost most of the G protein conserved and subgroup-specific epitopes but maintained the strain-variable epitopes. The two mutants had 10 or 11 nucleotide changes in the central region of the G protein gene when compared to the Long sequence, and almost all of those changes were different between the two mutants. The majority of the nucleotide changes involved A-G transitions (U-C in the positive sense) that resulted in amino acid substitutions. Each mutant had a total of six amino acid changes, and the changes were different between the two mutants. Unexpectedly, each mutant lost one of the four conserved cysteines of the G protein, and a different cysteine (Cys 182 or 186) was lost in each mutant. They are, in fact, the first reported RS viruses with only three cysteines in the G protein ectodomain. The genetic mechanism that generated the escape mutants and its relevance for the natural history of RS virus are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507282     DOI: 10.1006/viro.1994.1077

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  45 in total

1.  Specific cleavage of hyper-edited dsRNAs.

Authors:  A D Scadden; C W Smith
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.

Authors:  Michael N Teng; Peter L Collins
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 3.  RNA editing by adenosine deaminases that act on RNA.

Authors:  Brenda L Bass
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

Review 4.  Substitutional A-to-I RNA editing.

Authors:  Bjorn-Erik Wulff; Kazuko Nishikura
Journal:  Wiley Interdiscip Rev RNA       Date:  2010 Jul-Aug       Impact factor: 9.957

Review 5.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

6.  A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus.

Authors:  Roland C Zahn; Ina Schelp; Olaf Utermöhlen; Dorothee von Laer
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

Review 7.  Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase.

Authors:  Jean-François Gélinas; Guerline Clerzius; Eileen Shaw; Anne Gatignol
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

8.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Modification of retroviral RNA by double-stranded RNA adenosine deaminase.

Authors:  A M Hajjar; M L Linial
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

Review 10.  ADARs: viruses and innate immunity.

Authors:  Charles E Samuel
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.